Bausch Health Companies Inc. Deferred Tax Expense from Stock Options Exercised
Bausch Health Companies Inc. (BHC) reported Deferred Tax Expense from Stock Options Exercised of -$17.10 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-25.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:DeferredTaxExpenseFromStockOptionsExercised · last filed 2015-02-25
- Bausch Health Companies Inc. deferred tax expense from stock options exercised for fiscal 2014 was -$17.10M.
- Bausch Health Companies Inc. deferred tax expense from stock options exercised for fiscal 2013 was -$24.20M.
- Bausch Health Companies Inc. deferred tax expense from stock options exercised for fiscal 2012 was -$12.50M.
- Bausch Health Companies Inc. deferred tax expense from stock options exercised for fiscal 2011 was -$26.53M.
| Period end | Deferred Tax Expense from Stock Options Exercised 12 month | Deferred Tax Expense from Stock Options Exercised 12 month as first filed |
|---|---|---|
| 2014-12-31 | -$17.10M 10-K · filed 2015-02-25 | |
| 2013-12-31 | -$24.20M 10-K · filed 2015-02-25 | |
| 2012-12-31 | -$12.50M 10-K · filed 2015-02-25 | -$12.54M 10-K · filed 2014-02-28 |
| 2011-12-31 | -$26.53M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |